JNJ vs NBIS: Which Is the Better Buy?
Side-by-side comparison of Johnson & Johnson and Nebius Group N.V. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-08-06.
Johnson & Johnson · Healthcare
$253.85
-21.7% upside to fair value
Grade D
High Quality
VS
Nebius Group N.V. · Technology
$218.99
+11.9% upside to fair value
Med Conviction
Grade C+
QuantHub Verdict
NBIS has more upside to fair value
(+11.9%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
JNJ |
NBIS |
| Current Price |
$253.85 |
$218.99 |
| Fair Value Estimate |
$198.76 |
$245.00 |
| Upside to Fair Value |
-21.7%
|
+11.9%
|
| Market Cap |
$611.1B |
$52.6B |
| Forward P/E |
29.3x
|
—
|
| EV / EBITDA |
19.2x
|
—
|
| Price / Sales |
6.3x
|
59.9x
|
| Price / FCF |
34.3x
|
—
|
| Revenue Growth YoY |
+9.9%
|
+684.0%
|
| Gross Margin |
69.1%
|
48.0%
|
| Operating Margin |
26.9%
|
-68.8%
|
| Return on Equity |
26.3%
|
—
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
2.91%
|
-4.7%
|
| Analyst Consensus |
Buy
|
Buy
|
Investment Thesis
Johnson & Johnson is a leading healthcare conglomerate operating primarily in the drug manufacturing sector, known for its durable competitive moat supported by strong brand recognition and intangible assets. The company exhibits high business quality with a 26.3% return on equity and robust gross and net margins of 69.1% and 21.8%, respectively. However, earnings have faced significant pressure,…
Nebius Group is a fast-scaling neocloud GPU infrastructure provider spun out of Yandex's international assets, positioned at the center of the AI compute buildout with a validated capital relationship to Nvidia, which holds a 9.3% stake following a $2 billion investment. Revenue grew 684% year over year in Q1 2026 to $399 million, core AI cloud ARR reached $1.92 billion, and the company has locke…
Accumulation Zones
| Metric |
JNJ |
NBIS |
| Zone Low |
$149.07 |
$184.00 |
| Zone High |
$168.95 |
$208.00 |
| In Buy Zone? |
No
|
No
|